DSRV.io · Enforcement-informed quality intelligence
DSRVDSRV.io
Browse by regulation1 article · 1 high

21 CFR 211.165(b)

Every DSRV article whose Regulatory Snapshot cites 21 CFR 211.165(b): the enforcement case behind it, the inspection exposure it created, and what the desk would do about it.

Inspection exposure across the set
In brief
What has FDA cited under 21 CFR 211.165(b)?
1 DSRV article cite 21 CFR 211.165(b). Enforcement cases behind them: FDA Warning Letter 320-26-53 to Microbiological Testing & Consulting, LLC, March 16, 2026, and FDA Warning Letter 320-26-54 to Yangzhou H&R Plastic Daily Chemical Co., Ltd., March 18, 2026. Inspection exposure across them: 1 high.
What does DSRV recommend for 21 CFR 211.165(b)?
From the newest article (Contract Testing Labs Keep Exposing GMP Control Gaps): The control that matters is live oversight tiered by consequence: a lab generating release-critical data needs current evidence of reliability - recent oversight, meaningful performance review, clear escalation history - not an approved-vendor status that outlived the reality it describes. DSRV is decision support, not legal advice; verify against the official source each article names.
  1. 5 min readHigh exposure

    Contract Testing Labs Keep Exposing GMP Control Gaps

    Two March 2026 FDA-linked signals point to the same problem: contract testing oversight is still being treated as a paperwork exercise instead of a release-critical control. Small quality teams should read these cases as a warning about supplier qualification, data trust, and batch disposition risk.

    Case
    FDA Warning Letter 320-26-53 to Microbiological Testing & Consulting, LLC, March 16, 2026, and FDA Warning Letter 320-26-54 to Yangzhou H&R Plastic Daily Chemical Co., Ltd., March 18, 2026.
    DSRV take
    The control that matters is live oversight tiered by consequence: a lab generating release-critical data needs current evidence of reliability - recent oversight, meaningful performance review, clear escalation history - not an approved-vendor status that outlived the reality it describes.
Address this risk

Pressure-test your evidence before an inspector reads it

Bring the document that has to hold up under 21 CFR 211.165(b). DSRV maps the evidence, names the gaps, and routes judgment calls to human review. Controlled intake, no public file upload.

Apply for the Stability Pilot Ask The Vault about 21 CFR 211.165(b)

Regulatory intelligence and interpretation, not legal advice. Verify against the official FDA or ICH source each article names.